Adjuvanted influenza vaccines

From Original Antigenic Sin to the Universal Influenza Virus Vaccine

(2018) Carole Henry et al.   TRENDS IN IMMUNOLOGY

Inflammatory responses to influenza vaccination at the extremes of age

(2017) Jacqueline U. McDonald et al.   IMMUNOLOGY

A novel preservative-free seasonal influenza vaccine safety and immune response study in the frame of preclinical research

(2017) Gulbanu Sarsenbayeva et al.   JOURNAL OF MEDICAL VIROLOGY

Airway T cells protect against RSV infection in the absence of antibody

(2017) E Kinnear et al.   Mucosal Immunology

Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis

(2017) Alexander Domnich et al.   VACCINE

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine

(2017) Cecilia Montalban et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea

(2017) Won Suk Choi et al.   Human Vaccines & Immunotherapeutics

Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre

(2017) Victoria M. W. Gould et al.   Frontiers in Microbiology

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection

(2017) Rob Lambkin-Williams et al.   PLoS One

Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial

(2016) Ivan Fan-Ngai Hung et al.   LANCET INFECTIOUS DISEASES

Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant

(2016) David L. Gordon et al.   VACCINE

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

(2016) Judith Falloon et al.   VACCINE

Mechanistic insights into influenza vaccine-associated narcolepsy

(2016) S. Sohail Ahmed et al.   Human Vaccines & Immunotherapeutics

From discovery to licensure, the Adjuvant System story

(2016) Nathalie Garçon et al.   Human Vaccines & Immunotherapeutics

Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis

(2016) Kathryn E. Lafond et al.   PLOS MEDICINE

Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines

(2016) Saranya Sridhar   Frontiers in Immunology

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

(2016) Niels Peter H. Knudsen et al.   Scientific Reports

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination

(2015) Javier Díez-Domingo et al.   Influenza and Other Respiratory Viruses

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response

(2015) Lisa A. Jackson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

(2015) Beatris Mastelic Gavillet et al.   JOURNAL OF IMMUNOLOGY

BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study

(2015) Jenneke Leentjens et al.   JOURNAL OF INFECTIOUS DISEASES

Dissecting the Immune Response to MF59-adjuvanted and Nonadjuvanted Seasonal Influenza Vaccines in Children Less Than Three Years of Age

(2015) Luisanna Zedda et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine

(2015) Lei Li et al.   PLoS One

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2

(2015) Syed Sohail Ahmed et al.   Science Translational Medicine

The path forward

(2015) Ennio De Gregorio   VACCINE

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial

(2015) Joanne M. Langley et al.   VACCINE

RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection

(2015) Agnieszka Jozwik et al.   Nature Communications

H3N2 Mismatch of 2014–15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps

(2015) Hang Xie et al.   Scientific Reports

Influenza vaccination in children primed with MF59®-adjuvanted or non-adjuvanted seasonal influenza vaccine

(2015) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm

(2015) Tirth Raj Ghimire   SpringerPlus

Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets

(2015) Rebecca J. Cox et al.   PLoS One

Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

(2014) Emmanuelle Preaud et al.   BMC PUBLIC HEALTH

Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant

(2014) Robert B. Belshe et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

(2014) Karen K. Yam et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome

(2014) M. Kool et al.   JOURNAL OF IMMUNOLOGY

The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells

(2014) A. Seubert et al.   JOURNAL OF IMMUNOLOGY

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans

(2014) Edgar Turner Overton et al.   VACCINE

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children

(2014) Terry Nolan et al.   VACCINE

Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant

(2014) Karen Smith Korsholm et al.   VACCINE

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects

(2014) Sharon E. Frey et al.   VACCINE

Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection

(2014) Susanna Esposito et al.   VACCINE

Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune Responses, and Possible Vaccination Strategies

(2014) Stefan Niewiesk   Frontiers in Immunology

Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis

(2013) Andrea C Tricco et al.   BMC Medicine

Influenza virosomes as vaccine adjuvant and carrier system

(2013) Christian Moser et al.   Expert Review of Vaccines

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

(2013) Spyros A. Kalams et al.   JOURNAL OF INFECTIOUS DISEASES

Cellular immune correlates of protection against symptomatic pandemic influenza

(2013) Saranya Sridhar et al.   NATURE MEDICINE

Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells

(2013) A. S. McKee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial

(2013) William H. Yang et al.   VACCINE

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

(2013) Samuele Calabro et al.   VACCINE

Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant

(2013) Fangjia Lu et al.   VACCINE

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant

(2013) John J. Treanor et al.   VACCINE

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

(2013) E. Miller et al.   BMJ-British Medical Journal

Mechanisms of Action of Adjuvants

(2013) Sunita Awate et al.   Frontiers in Immunology

Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains

(2012) J. J. Treanor et al.   CLINICAL INFECTIOUS DISEASES

Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008

(2012) Hong Zhou et al.   CLINICAL INFECTIOUS DISEASES

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

(2012) Nathalie Garçon et al.   Expert Review of Vaccines

The history of MF59®adjuvant: a phoenix that arose from the ashes

(2012) Derek T O’Hagan et al.   Expert Review of Vaccines

Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro

(2012) Tirth R. Ghimire et al.   IMMUNOLOGY LETTERS

Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine

(2012) Jacob Atsmon et al.   JOURNAL OF CLINICAL IMMUNOLOGY

AF03, An Alternative Squalene Emulsion‐Based Vaccine Adjuvant Prepared by a Phase Inversion Temperature Method

(2012) Marie‐Françoise Klucker et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

(2012) Tom M Wilkinson et al.   NATURE MEDICINE

Structural vaccinology starts to deliver

(2012) Philip R. Dormitzer et al.   NATURE REVIEWS MICROBIOLOGY

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to ,9 Years of Age

(2012) Cynthia Nassim et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

(2012) David N. Taylor et al.   VACCINE

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant

(2012) David L. Gordon et al.   VACCINE

Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

(2012) Hideyuki Ikematsu et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and Efficacy in Hemodialysis Patients of an AS03A-Adjuvanted Vaccine for 2009 Pandemic Influenza A(H1N1): A Nonrandomized Trial

(2011) Ralf Dikow et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Antigen depot is not required for alum adjuvanticity

(2011) Sharon Hutchison et al.   FASEB JOURNAL

T-cell-inducing vaccines - what’s the future

(2011) Sarah C. Gilbert   IMMUNOLOGY

Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study

(2011) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

(2011) A. Seubert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59

(2011) A. H. Ellebedy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis

(2011) W.E.P. Beyer et al.   VACCINE

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

(2011) Samuele Calabro et al.   VACCINE

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness

(2011) J.M. Langley et al.   VACCINE

Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults

(2011) Christine B. Turley et al.   VACCINE

Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens

(2011) L.R. Stanberry et al.   VACCINE

Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation

(2010) Willemijn van den Ancker et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Influenza and Meningococcal Vaccinations Are Effective in Healthy Subjects Treated with the Interleukin-1 -Blocking Antibody Canakinumab: Results of an Open-Label, Parallel Group, Randomized, Single-Center Study

(2010) A. Chioato et al.   Clinical and Vaccine Immunology

AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age

(2010) François Roman et al.   CLINICAL INFECTIOUS DISEASES

The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants

(2010) Roberto Spreafico et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

(2010) Philippe Moris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months

(2010) Alfonso Carmona et al.   VACCINE

Plasmodium falciparum-Specific Cellular Immune Responses after Immunization with the RTS,S/AS02D Candidate Malaria Vaccine in Infants Living in an Area of High Endemicity in Mozambique

(2009) A. Barbosa et al.   INFECTION AND IMMUNITY

Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin

(2009) David J. M. Lewis et al.   PLoS One

Antibody Recognition of a Highly Conserved Influenza Virus Epitope

(2009) D. C. Ekiert et al.   SCIENCE

Trivalent inactivated subunit influenza vaccine Influvac®: 25-Year experience of safety and immunogenicity

(2009) K.M. Giezeman et al.   VACCINE

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch

(2009) Gregory M. Glenn et al.   VACCINE

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans

(2009) Robert B. Couch et al.   VACCINE

Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine

(2009) Christian Herzog et al.   VACCINE

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial

(2009) François Roman et al.   VACCINE

Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 Season

(2008) Edward A. Belongia et al.   JOURNAL OF INFECTIOUS DISEASES

Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma

(2008) Miguel-Angel Perales et al.   MOLECULAR THERAPY

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

(2008) Stephanie C. Eisenbarth et al.   NATURE

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice

(2008) Karin Riedl et al.   VACCINE

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE